Fluticasone furoate, umeclidinium, and vilanterol

(Trelegy Ellipta®)

Fluticasone furoate, umeclidinium, and vilanterol

Latest News

loading GIF

Drug updated on 5/17/2024

Dosage FormPowder (inhalation; fluticasone furoate/ umeclidinium/ vilanterol; 100/62.5/25 mcg); Powder (inhalation; fluticasone furoate/ umeclidinium/ vilanterol; 200/62.5/25 mcg)
Drug ClassCorticosteroid, anticholinergic and long-acting beta2-adrenergic agonists
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
  • Indicated for the maintenance treatment of asthma in patients aged 18 years and older.

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Fluticasone furoate, umeclidinium, and vilanterol (Trelegy Ellipta) is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) and asthma in individuals aged 18 years and older. It has shown superiority over multiple triple therapy comparators in increasing trough FEV1 from baseline at 24 weeks.
  • Two studies focused on the comparative effectiveness and safety of ICS/LABA/LAMA triple therapy combinations for COPD treatment, specifically fluticasone furoate/umeclidinium/vilanterol.
  • Trelegy Ellipta demonstrated significant improvements in the annualized rate of combined moderate or severe exacerbations compared to standard single-inhaler triple therapy and dual therapies. This suggests it may be more effective than some other treatments at managing COPD exacerbation rates.
  • The drug also showed notable improvements in mean St. George's Respiratory Questionnaire scores indicating better patient-perceived quality of life compared to other triple therapies. Additionally, there was a significant reduction in the use of rescue medication, suggesting better symptom control.
  • When directly compared to Budesonide/Glycopyrronium/Formoterol (BGF MDI), no statistically significant differences were found in reducing exacerbations, improving lung function, or symptom management according to one study analyzed.
  • The analyses predominantly focused on adults aged at least 40 years with moderate-to-severe COPD, indicating that findings can likely be generalized across the adult population suffering from this condition without further segregation into subgroups.